

Product Data Sheet

Product Name: ML 239
Cat. No.: GC17468

Chemical Properties

Cas. No. 1378872-36-6

Chemical Name (1Z,N'E)-N'-((1H-pyrrol-2-yl)methylene)-2-(2,4,6-trichlorophenoxy)acetohydrazonic acid

SMILES C1C=CC(Cl)=C(OC/C(O)=N/N=C([H])/C2=CC=CN2)C(Cl)=C1


Formula $C_{13}H_{10}Cl_3N_3O_2$ M.Wt 346.6

Solubility DMSO: 10 mg/ml Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell experiment: Cancer cell lines (CCLs) are plated at a density of 500 cells/well in white opaque tissue-culture-treated Aurora 1536-well MaKO plates in the provider-recommended growth media using a highly automated platform. Compounds (ML239) are added by acoustic transfer using a Labcyte Echo 555. 24 hours after plating. The effects of small molecules (ML239) are measured over a 16-point concentration range (two-fold dilution) in duplicate. DMSO is used at a constant concentration of 0.33%, including vehicle-only control wells. As a surrogate for viability, cellular ATP levels are assessed 72 hours after compound transfer by addition of CellTiterGlo followed by luminescence measurement using a ViewLux Microplate Imager. Duplicates are averaged and luminescence values normalized to vehicle (DMSO) treatment and background (media-only) wells[2].

References:

- [1]. Germain AR, et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. *Bioorg Med Chem Lett*. 2012 May 15;22(10):3571-4.
- [2]. Rees MG, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. *Nat Chem Biol*. 2016 Feb;12(2):109-16.

Background

ML239 is the best-in-class inhibitor of the breast cancer stem cells with an $IC_{50} = 1.16 \mu M$. [1]

ML239 was a selective inhibitor an $IC_{50} = 1.18 \mu M$ against HMLE_sh_ECad, demonstrated a >23-fold selectivity over the control line, and was toxic to another CSC-like line, HMLE_shTwist, and a breast carcinoma cell line, MDA-MB-231. Five genes (*ATP6V0C*, *PKM2*, *PPDPF*, *RPL23*, and *SERINC2*) were differentially regulated in HMLE_sh_GFP after treatment with ML239. Gene expression studies conducted with ML239-treated cells showed altered gene expression in the NF- κ B pathway in the HMLE_sh_ECad line but not in the isogenic control line. ML239 was selectively toxic toward another CSC-like cell line, HMLE_Twist, and the breast cancer line, MDA-MB-231. Similar to the results observed in the HMLE_sh_ECad cell line, ML239 was potently toxic, inhibiting HMLE_Twist with an $IC_{50} \sim 0.1 \mu M$. ML239 displayed potent toxicity ($IC_{50} = 2.81 \mu M$) to the breast carcinoma cell line, MDA-MB-231 [1]. ML239 also alters the expression of genes in the NF- κ B, MAPK and inflammatory

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

cytokine pathways.

Reference:

1. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen. 2012 Oct;17(9):1204-10. Epub 2012 Aug 30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA